These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15077282)

  • 1. Genetic markers of treatment response in rheumatoid arthritis.
    Bridges SL
    Arthritis Rheum; 2004 Apr; 50(4):1019-22. PubMed ID: 15077282
    [No Abstract]   [Full Text] [Related]  

  • 2. Personalized medicine in rheumatoid arthritis: hopes and challenges.
    Bridges SL
    Bull NYU Hosp Jt Dis; 2007; 65(3):174-7. PubMed ID: 17922665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis.
    Tsukahara S; Ikari K; Sato E; Yamanaka H; Hara M; Tomatsu T; Momohara S; Kamatani N
    Ann Rheum Dis; 2008 Dec; 67(12):1791-2. PubMed ID: 19005160
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P
    Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor alpha haplotypes versus tumor necrosis factor alpha -308 G/A polymorphism in the prediction of infliximab treatment efficacy in rheumatoid arthritis.
    Mugnier B; Roudier J
    Arthritis Rheum; 2004 Dec; 50(12):4075-6; author reply 4076-7. PubMed ID: 15593229
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacogenomics of methotrexate in rheumatoid arthritis: does race make a difference?
    Dervieux T
    J Rheumatol; 2008 Apr; 35(4):550-2. PubMed ID: 18398948
    [No Abstract]   [Full Text] [Related]  

  • 7. Gene analysis for exploring the effects of drugs in rheumatoid arthritis.
    Ospelt C; Neidhart M; Gay RE; Gay S
    Arthritis Rheum; 2005 Aug; 52(8):2248-56. PubMed ID: 16052564
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacogenetic approaches to rheumatoid arthritis.
    Taniguchi A; Kamatani N
    Pharmacogenomics J; 2004; 4(6):350-3. PubMed ID: 15249925
    [No Abstract]   [Full Text] [Related]  

  • 9. Early rheumatoid arthritis.
    Mitchell KL; Pisetsky DS
    Curr Opin Rheumatol; 2007 May; 19(3):278-83. PubMed ID: 17414956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The response to anti-TNF-alpha treatment: gene regulation at the bedside.
    de Vries N; Tak PP
    Rheumatology (Oxford); 2005 Jun; 44(6):705-7. PubMed ID: 15855186
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to the commentary 'Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind'.
    Vander Cruyssen B; Durez P; Westhovens R; Vastesaeger N; Geldhof A; De Keyser F
    Arthritis Res Ther; 2006; 8(6):406. PubMed ID: 17049071
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic epidemiology of rheumatoid arthritis.
    Oliver JE; Worthington J; Silman AJ
    Curr Opin Rheumatol; 2006 Mar; 18(2):141-6. PubMed ID: 16462519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Hider SL; Bruce IN; Silman AJ; Symmons DP
    J Rheumatol; 2005 Jan; 32(1):6-10. PubMed ID: 15630715
    [No Abstract]   [Full Text] [Related]  

  • 14. [Progress due to genetic research on rheumatoid arthritis: hype or hope?].
    Jacobs JW; Huizinga TW; Bijlsma JW; van der Helm-van Mil AH
    Ned Tijdschr Geneeskd; 2009; 153():A206. PubMed ID: 19785838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis.
    Kang CP; Lee KW; Yoo DH; Kang C; Bae SC
    Rheumatology (Oxford); 2005 Apr; 44(4):547-52. PubMed ID: 15695296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacogenetics of methotrexate.
    Hider SL; Bruce IN; Thomson W
    Rheumatology (Oxford); 2007 Oct; 46(10):1520-4. PubMed ID: 17586865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?
    Bansard C; Lequerré T; Daveau M; Boyer O; Tron F; Salier JP; Vittecoq O; Le-Loët X
    Rheumatology (Oxford); 2009 Sep; 48(9):1021-8. PubMed ID: 19483089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic markers and clinical relevance in rheumatoid arthritis.
    Guo J; Li Z
    Int J Rheum Dis; 2016 Feb; 19(2):109-13. PubMed ID: 26620943
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.